Kornimate/medical-research-clean huggingface dataset:
metabolic workup in patients suffering from kidney stone disease and osteopenia

Conditions: Urolithiasis; Renal Colic; Osteopenia

Summary: patients suffering from acute renal colic are evaluated by non contrast computerized tomography with excellent identification rates of urinary stones. the scan also covers the bones of the ribs, spine and pelvis, allowing measurements of the bone density and identifying early osteopenic changes. bone demineralization is associated with metabolic changes such as hypercalcemia or hypercalcuria. in this study the investigators will look for correlation between kidney stones, osteopenic bone changes and metabolic abnormalities.

kidney stones are a common medical condition found in more then 5% of the adult population. the stones might cause severe pain (due to acute obstruction of a renal unit) , deterioration of renal function and urinary tract infection. one of the causes of kidney stones is metabolic changes such as hypercalcemia or hyperoxaluria. basic evaluation of kidney stones patients include measurements of calcium, phosphor and uric acid in the serum and is often negative. thorough metabolic workup including 24 hours urine collection is not cost effective and is reserved for patients with frequent recurrence of stone disease. metabolic abnormalities are often associated with bone demineralization, of which the patients are typically unaware. such changes can be detected by the ct scan. on the same scan, performed for identifying the stone, the radiologist can measure bone density, using the hounsfield units, in the l2 vertebral body of and the acetabular area of the pelvis. in the study, in all patients undergoing ct scan due to renal colic, the bone density will be measured. patients with abnormal bone density will undergo a complete metabolic workup including 24 hours collection of urine and measurements of urinary clearance of calcium, phosphorous, uric acid, oxalate and citrate . the investigators will look for correlation between osteopenic changes and metabolic abnormalities.

Eligibility criteria:
inclusion criteria: * 18 years or old * informed consent * kidney stones * ct scan positive for stones and bone changes exclusion criteria: * under 18 * unable to sign * no stones detected on scan (even if a stone was expelled recently) * no bone changes * pregnancy * a patient already known to suffer from metabolic bone disease * a patient with documented osteoporosis * patients following spinal or pelvic trauma / surgery

Keywords: urolithiasis metabolic abnormalities osteopenia hypercalcemia hypercalcuria bone density
a study of tralokinumab when delivered subcutaneously at different flow rates to healthy volunteers

Conditions: Asthma; Healthy Subjects or Volunteers

Summary: the primary objective of this study is to evaluate the pharmacokinetics (pk) and tolerability of tralokinumab when delivered subcutaneously at different flow rates to healthy volunteers.

this is a phase 1, open-label, assessor-blind, parallel-group study to evaluate the pk and tolerability of a single subcutaneous dose of 300 milligram (mg) tralokinumab when delivered as a 2 milliliters (ml) injection at different flow rates to healthy adult volunteers.

Eligibility criteria:
key inclusion criteria: * healthy males and females ages 19-65 years * body mass index of 19.0-30.0 kilogram per meter square (kg/m\^2) * no clinically significant abnormality * vital signs, electrocardiogram (ecg), and laboratory parameters within normal range * negative alcohol and drug screens * females of childbearing potential who are sexually active with a nonsterilized male partner must use highly effective contraception * nonsterilized males who are sexually active with a female partner of childbearing potential must use highly effective contraception. key exclusion criteria: * concurrent enrollment in another clinical study where the subject is receiving an investigational product * receipt of any marketed or investigational biologic agent within 4 months or 5 half-lives prior to screening, whichever is longer * receipt of any investigational nonbiologic agent within 3 months or 5 half-lives prior to screening, whichever is longer * current use of regular pain-modifying, anti-depressant, anxiolytic, or hypnotic medication * history of thrombocytopenia or bleeding disorder or use of anticoagulants * history of any immunodeficiency disorder or use of immunosuppressive medication. * history of a clinically significant infection * history of cancer * positive hepatitis b or c * positive hiv

Keywords: asthma healthy subjects or volunteers tralokinumab cat-354
individualized blood glucose control in icu. the controling study. a double blinded multicentric randomized study.

Conditions: Critical Illness

Summary: during the last 2 decades, the management of hyperglycemia in critically ill patients has become one of the most discussed topics in the intensive-care field. the initial data suggesting significant benefit from the normalization of blood glucose levels in critically ill patients using intensive intravenous insulin therapy (van den berghe g et al. n engl j med. 2001) has been tempered by later studies (finfer s et al. n engl j med. 2009). some studies suggested that strict blood glucose control might benefit in non-diabetic patient and worsen outcomes in diabetics. we hypothesized that an individualized blood glucose target based on glycated hemoglobin measured at icu admission would improve outcome when compared to a standard care of maintaining blood glucose bellow 10 mmol/l (180 mg/dl). we designed a randomized double blinded study in which blood glucose control is piloted in both groups by a web-guided protocol that directly gives instruction to nurses (https://extranet.chu-lyon.fr/cpg). the study will enroll 4200 patients in 10 centers. primary end point is 90 d outcome after randomization.


Eligibility criteria:
inclusion criteria: patients are eligible for inclusion in the study if all the following criteria are met: * patient is 18 year old or older; * at time of the patient's admission to the icu the treating icu specialist expects the patient will require treatment in the icu that extends beyond the calendar day following the day of admission. exclusion criteria: * patients will be excluded from the study if one or more of the following criteria are present: * patient or legal surrogate decision maker does not accept the participation to the study; * imminent death (anticipated in less than 48 hours); * the treating clinicians are not committed to full supportive care (no resuscitation, no renal replacement therapy limits in dose of vasoactive support); * patient is expected to be eating before the end of the day following admission; * admission in icu for hypoglycemic encephalopathy or patient at risk for hypoglycaemia ( e.g. known insulin secreting tumour or history of unexplained or recurrent hypoglycaemia or fulminant hepatic failure); * if a patient has previously been enrolled in the controling study (patients cannot be enrolled in the controling study more than once).

Keywords: blood glucose target icu insulin hypoglycemia hyperglycemia glycated hemoglobin
efficacy of intermittent fasting on metabolic disease

Conditions: Individuals With Metabolic Disease

Summary: to elucidate the health effects, and further explore the research on safety. this study was conducted among adults with metabolic disease by using the intermittent fasting for 4 weeks. the aim of this study is to provide scientific basis for the if used as a new prevention and control technology for metabolic disease.

in this trail, participants with metabolic disease were enrolled for 4-week intermittent fasting intervention. the intermittent fasting plains include time-restricted fasting and 5:2 project. for trf regimen, participants are allowed to eat ad libitum from 7am to 5pm and fast in other time. for 5:2 project, chose two non-consecutive days per week to eat very little and eat ad libitum the other 5 days of the week. serum samples and feces samples were collected before and after intervention for analysis.

Eligibility criteria:
inclusion criteria: * adults aged between 18 to 75 years old with metabolic disease exclusion criteria: * diet therapy before participation * pregnancy * severe hepatic diseases * severe nephropathy * organic digestive diseases * autoimmune diseases * cancer * infectious diseases, including pulmonary tuberculosis and aids * alcoholism * continuous antibiotic use for over 3 days within 3 months prior to enrollment * continuous use of a weight-loss drug for over 1 month * gastrointestinal surgery

Keywords: intermittent fasting metabolic disease
impact of the covid-19 epidemic on glycemic balance and the level of stress in diabetic patients

Conditions: Diabetes

Summary: prospective, non-interventional, multicentric study

the rapid spread of the covid-19 pandemic and the isolation at home implemented in france, creates unprecedented challenges for diabetic patients. patients with diabetes have been considered to be at higher risk of infection by the virus, with a greater risk of mortality; this has been a great source of anxiety for them. it is well known that stress has an impact on plasma glucose levels. the french situation where a general confinement has been decreed over the whole territory (which is not the case for all countries) and for a period of two months, makes it possible to study the impact of this unique situation on stress, sedentary lifestyle, changes in diet and decrease in physical activity. there are no similar experiences described in the literature. the investigators hypothesize there will be an increase of hba1c in the coming months. the main objective is to assess changes in glycemic control in diabetic patients after the confinement period. the secondary objectives are to: * evaluate the prevalence of a state of psychological distress (which could be described as post-traumatic) following this epidemic situation in a population of patients with diabetes and to determine the main characteristics of patients with such a state of psychological distress. * study the evolution of the psychological state at a distance from confinement (6 months later) with the same questionnaire. * analyze characteristics of lifestyle during confinement: food (snacking), frequency of leaving home, sleep disorders and assess a possible association with variations in hba1c. this is an observational, prospective, multicenter study. participation in the study will be offered to all consecutive patients seen in diabetes consultations, who meet the selection criteria.

Eligibility criteria:
inclusion criteria: * adult patient (≥ 18 years old) * diabetic patient (type 1 or type 2) regardless of their diabetes treatment who experienced complete confinement in their own home, in france. * patients who had a measured hba1 or an estimated hba1c with a glucose sensor freestyle libre with a known result, between november 1, 2019 and february 29, 2020. * patients agreeing to have their hba1c measured between may 15 and july 31, 2020. * having been informed of the study and not objecting to participating in it exclusion criteria: - adults over the age of legal protection (safeguard of justice, curatorship, guardianship), persons deprived of their liberty.

Keywords: covid 19 diabetes stress hba1c
autologous cytokine induced killer cells (cik) for patients with severe psoriasis

Conditions: Psoriasis; Adoptive Immunotherapy

Summary: to determine the therapeutic roles of cik cells on patients with psoriasis


Eligibility criteria:
inclusion criteria: * have ever had a physician's diagnosis of chronic moderate to severe plaque psoriasis and be a candidate for treatment with cik are being treated with or initiating cik therapy at the time of enrollment be able to provide written informed consent be willing and able to fully to participate for the duration of patient follow-up (5 years) exclusion criteria: * puva or grenz ray therapy within 4 weeks prior to randomisation. uvb therapy within 2 weeks prior to randomisation. systemic treatment with biological therapies (marketed or otherwise) with a possible effect on psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 3 months prior to randomisation. systemic treatment other than biologicals with a possible effect on psoriasis (e.g., corticosteroids, vitamin d analogues, retinoids, hydroxycarbamide, azathioprine, meth-otrexate, cyclosporine, other immunosuppressants) within 4 weeks prior to randomisation. any topical treatment of the scalp (except for medicated shampoos and emollients) within 2 weeks prior to randomisation (medicated shampoos/emollients are not allowed during the double-blind phase). shampoos containing corticosteroids, e.g. clobex®, are not allowed within 2 weeks prior to randomisation. planned use of topical treatment for psoriasis of the trunk or limbs, besides study medication, during the study with the exceptions of: • emollient • medications used to treat psoriasis of the skin folds and/or genitals (any medication may be used for this purpose apart from class 1-5 corticosteroids. topical treatment of the face with class 1-5 corticosteroids within 2 weeks prior to randomisation. planned initiation of, or changes to, concomitant medication that could affect psoriasis (e.g., beta blockers, anti-malaria drugs, lithium) during the double-blind phase of the study. treatment with any non-marketed drug substance (i.e., an agent which has not yet been made available for clinical use following registration) within 4 weeks prior to randomisation. planned use of chemical treatments of the hair (eg relaxers, 'perms', or colourings) during the double-blind phase of the study. current diagnosis of erythrodermic, exfoliative or pustular psoriasis. patients with any of the following conditions also present on psoriatic areas of the scalp or trunk/limbs: viral (e.g. herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to tuberculosis or syphilis, rosacea, acne rosacea, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, ulcers or wounds. other inflammatory skin diseases that may confound the evaluation of psoriasis of the scalp or trunk/limbs.
retrospective review of nsaids in the postpartum period

Conditions: Post Partum Pain

Summary: chart review of women who have delivered an infant in a single health care system to determine if nsaid use increases blood pressures in the postpartum period.

nonsteroidal anti-inflammatory drugs (nsaids) are the most common medication used for pain relief in the postpartum period in the united states. for pain relief of uterine involution, nsaids have shown to be superior to placebo, and equivalent or superior to narcotics. in 2013 the american college of obstetricians and gynecologists (acog) discouraged the use of nsaids in women with pre-eclampsia due to concerns for inadvertently increasing blood pressure. this recommendation is based on non-obstetrics literature, which tended to show a small increase of blood pressures in patients who use nsaids. however the literature is mixed, particularly on ibuprofen which is the most common nsaid used in the postpartum. of the two meta-analysis that are commonly referenced, pope et al found a decrease of -0.3 (+/- 2.57) mmhg in mean arterial pressure (map) in patients with hypertension treated with ibuprofen, and johnson et al identified an average of 5mmhg increase in blood pressure with ibuprofen use. a large study of 18,325 patients who were treated with nsaids or cox-2 inhibitors, found an average of a 2.1 (+/- 0.5) mmhg increase in blood pressure with ibuprofen administration. there are two articles available in the obstetrics literature on the topic of nsaids in women with hypertension disorders. the first is by makis et al, and is a case series of six women, with discussion of two cases. the explanations of hypertension causes are limited and possible alternate diagnoses are not discussed (6). the second by wasden et al is a retrospective study of women who had the diagnosis of severe hypertension disorders in pregnancy. the patients were matched 2:1 for women exposed to nsaids versus those who did not receive nsaids. maps were compared, and there was no difference found between the two groups. this second study is better designed and is likely representative of the true outcome of nsaid use in pre-eclamptic women, as the general literature shows a small, non-clinically significant change in blood pressure readings.

Eligibility criteria:
inclusion criteria: * received nsaids post delivery for pain exclusion criteria: -
the effectiveness of bu zhong yi qi tang in patients with myasthenia gravis

Conditions: Myasthenia Gravis

Summary: research background: according to the myasthenia gravis foundation of america (mgfa, 2015), the estimated prevalence of myasthenia gravis is 14-20 per 100,000 people, with a higher prevalence in young female individuals compared to males. however, as individuals age, especially after the age of 50, the prevalence in males becomes higher than in females. myasthenia gravis patients often experience varying degrees of disability, leading to the need for long-term medical care, medication, and lifestyle adjustments. this also gives rise to subsequent challenges in caregiving, affecting both the patients' families and society.

:this study aims to assess the effectiveness of using a combination of traditional chinese and western medicine,to improve the meridian energy and autonomic nervous system function of myasthenia gravis patients.

Eligibility criteria:
inclusion criteria: * patients diagnosed with ocular myasthenia by a doctor * western medicine prescriptions only take oral mestinon (pyrido stigmine bromide) * patients over 20 years old * can understand and understand those who can speak mandarin or taiwanese * those with a clear state of consciousness and no diagnosis of mental illness * patients and their families who are willing to receive precise integrated treatment of traditional chinese and western medicine. exclusion criteria: * patients with liver failure or kidney failure * allergy symptoms to traditional chinese medicine, such as skin itching and redness * patients with malignant tumors * patients currently undergoing radiotherapy and chemotherapy * pregnant * cardiac rhythm device implementer
topical tranexamic acid for the prevention of postpartum hemorrhage in women with twin pregnancy

Conditions: Cesarean Section Complications

Summary: twin pregnant women requesting cesarean section, the effectiveness and safety of temporary uterine packing coupled with topical tranexamic acid as an adjuvant for decreasing blood loss during delivery were compared to placebo.

the most common cause of postpartum hemorrhage (pph) is uterine atony, which accounts for up to 80% of pph occurrences. pph is the main cause of maternal morbidity and mortality, accounting for up to 28% of all maternal deaths globally. as a result, generating a fast and efficient uterine contraction after birth is critical. obesity, white or hispanic race/ethnicity, polyhydramnios, preeclampsia, anemia, and chorioamnionitis, as well as a twin pregnancy, are all risk factors for uterine atony.

Eligibility criteria:
inclusion criteria: * women with twin pregnancy undergoing cesarean section exclusion criteria: * patients with cardiac, hepatic, renal, or thromboembolic disease. , * patients with a high possibility of the morbid adherent placenta, * known coagulopathy and * those presented with severe antepartum hemorrhage * refuse to participate
addition of platelet rich plasma (prp) in microfat lipofilling (mg) in the treatment of cranial flap scars: a randomized, double-blind, superiority study

Conditions: Facial Lipofilling

Summary: the objective is to show the superiority of the prp + microfat (mg) mixture compared to microfat alone, in the filling of large subcutaneous depressions of the face and skull. the investigators chose to study the post neurosurgical sequelae after removal and reinstallation of the cranial flap, with, for example, damage to the temporal muscle and asymmetry of the temples or sinking of the cranial flap

this clinical superiority study will be conducted in a double-blind, randomized fashion. the follow-up of each patient will be 6 months post injection. 22 patients will be included and randomized into 2 arms: prp + microfat or microfat alone. the primary endpoint will be assessed by a radiologist in a blinded fashion, using 3 mri scans: the month before the procedure, the day after, and at 6 months (time at which fat resorption decreases).

Eligibility criteria:
inclusion criteria: * men and women of age * desiring a procedure with an aesthetic aim * having a minimum of 6 months after the neurosurgical procedure for cranial flap replacement * in the absence of need for neurosurgical revision, * informed consent signed by the patient * be affiliated with the health insurance exclusion criteria: * contraindication to mri * patients who have already undergone lipofilling at the site of interest before inclusion in the study. * contraindication to general anesthesia * considered neurosurgical revision * carcinological neurosurgery (with the exception of benign tumors with complete excision and/or non-evolving residue requiring no further treatment) * healing of the site of interest not acquired at the 1st consultation * bmi \> 35 * thrombocytopenia\< 150 g/l * thrombocytosis \> 450 g/l * known thrombopathy * hb anemia \< 10g/dl * active hiv1 and 2 infections, agp24, hcv ac, hbs ag and achbc, htlv i and ii ac, tpha * chronic treatment with corticoids or nsaids or anticoagulant * immune deficiency * infectious diseases * minors * pregnant or breastfeeding women * patient participating in another clinical trial